CClinicalTrials.gg
CompletedNCT06324929CARRIINativeUpdated Jun 17, 2026

Optimizing a Digital AEP Risk Intervention With Native Women and Communities

An interventional study of CARRII Native Rapid Pilot Testing in Alcohol Exposed Pregnancy, Unplanned Pregnancy and Alcohol Use, Unspecified, sponsored by University of Virginia. Completed at 1 site in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University of Virginia · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

The purpose of Aim 1 of the study is to gather quantitative and qualitative information to inform the development of a digital app tailored for Native American women to help them avoid a pregnancy affected by alcohol. In Aim 2, we will Pilot test 5 new candidate components tailored to Native women at risk of AEP

Read the detailed description

Alcohol exposed pregnancy (AEP) can result in Fetal Alcohol Spectrum Disorders (FASDs) that cause lifelong costly disabilities from brain, organ, tissue, and neurological damage. While over 3.3 million US women per month are at risk for AEP, risk for AEP among Native American (Native) women is higher, due to low contraception use and high binge drinking rates. For example, 20% of sexually active Native women in the Southwestern US are at risk for AEP, and 52% of pregnancies in the Navajo Nation are unplanned, compared to 45% nationally. Among pregnant women from Great Plains tribes, nearly 30% drink at binge levels and do not use contraception to prevent pregnancy. Among another sample of Native women from Great Plains tribes, 65% were sexually active, not seeking pregnancy, and not using contraception.

For Aim 1 we will implement four study methods to evaluate and tailor CARRII digital intervention components for Native women and prepare them to be used in a subsequent trial. These iterative mixed methods formative studies include:

  1. Develop an ongoing Native Partners Working Group to review study plans and findings over time with the research team,
  2. Collect quantitative surveys from Native women to estimate rates of AEP risk, interest/ ability to participate, health literacy, and other factors (n=300),
  3. Conduct Focus Groups to prototype and tailor new CARRII components (up to n=60), and
  4. Conduct Think-aloud User Testing (n=20) to finalize a draft of the CARRII Native intervention to prepare for development on a responsive design platform.

After incorporating input from participants (SA 1) and the Native Partners Working Group, we will pilot candidate components (SA2) to assess independent effects on AEP behavioral risk factors (drinking and contraception) while considering practical aspects such as frequency and duration of contact with participants, and costs of each component.

AEP can be prevented by avoiding an unintended pregnancy or reducing alcohol intake by those who may become pregnant. PI Ingersoll was a PI on the seminal CHOICES study that developed the first efficacious theory-based AEP intervention, with 4 Motivational Interviewing (MI) counseling sessions. PI Hanson adapted CHOICES for Native women in tribal communities. The Native-adapted CHOICES reduced AEP risk among Native women, but was too costly to sustain for high-risk women and communities.

In contrast, theory-based digital interventions are highly accessible, more convenient, scalable, and more sustainable, while still efficacious. In R34AA020853, Ingersoll piloted the first automated digital AEP intervention, CARRII. A nationwide pilot randomized controlled trial (RCT) showed that CARRII (but not the education control) significantly reduced AEP risk and pregnancy risk at 3 and 6 months, and drinking risk at 3 months. However, CARRII was studied among general population women, and not Native American women specifically.

Because rates of unintended pregnancy and binge drinking that create AEP risk are inequitable between Native women and the general population, CARRII will be tailored to and optimized for this priority subgroup. Guided by the Multiphase Optimization Strategy (MOST), we will tailor CARRII's existing components for Native women and systematically test proposed novel components (derived from formative work with Native women), to develop an efficient and scalable intervention tailored to Native women at risk of AEP. Optimizing CARRII for Native women will require measuring the efficacy and costs of components to find a balance between impact and affordability for Native communities. The overarching goal of this R61/R33 proposal is to determine the optimal combination of novel intervention strategies to include with CARRII (tailored for Native women) that maximizes digital intervention efficacy at feasible cost for Native communities. Achieving R61 milestones will permit progression to the R33 phase.

02

Conditions studied

  • Alcohol Exposed Pregnancy
  • Unplanned Pregnancy
  • Alcohol Use, Unspecified
  • Contraception Use
  • Sexual Behavior

Keywords

  • Native American
  • female
  • adult
  • contraception
  • alcohol
  • digital intervention
  • optimization
  • mHealth (mobile health)
03

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for survey:

  • Native American

Inclusion Criteria for rapid pilot testing:

  • Native American
  • Risk for Alcohol Exposed Pregnancy

Exclusion Criteria:

-

04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
407 participants (actual)

Study arms

  • No intervention
    Aim 1 Survey

    We will enroll up to 300 Native women ages 18-44 to complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control

  • Experimental
    Rapid Pilot Testing

    Participants will complete a baseline past month TLFB (timeline follow-back) of alcohol use and contraception use during sex and a short online survey evaluating knowledge about AEP risk, intentions to change, self-efficacy for change, and readiness to change alcohol use and contraception behaviors. Each cohort of 10 participants will receive one of the 5 novel components (telephone-administered TLFB 2 weeks after study enrollment, mailed pregnancy test arriving 10-14 days after enrollment, digital safer sex and drink reduction skills training accessible across the 6-week period, automated texting prompting usage of skills across the 6-week period, or anonymized community message board across the 6-week period). Participants will complete a second TLFB for the past 6 weeks, and a short survey to rate the component they experienced, a System Usability Scale on their component, and measures of short-term knowledge, intentions to change, self-efficacy for change, and readiness to change.

    Behavioral: CARRII Native Rapid Pilot Testing

Interventions

  • BehavioralCARRII Native Rapid Pilot Testing

    The candidates that will be tested are: 1) Telephone-administered 30 day timeline follow-back of drinking, sex, and contraception, administered by phone at enrollment and monthly, which should increase awareness of AEP risk and motivation for alcohol and contraception behavior change, 2) Mailed pregnancy tests sent monthly to raise consciousness of pregnancy risk and to detect a new pregnancy early, which should increase motivation for contraception behavior change, 3) Automated, personalized digital safer sex and drink counting/reduction skills training, to improve drinking self-management skills and self-efficacy for drinking reduction and contraception use, 4) Fully automated text messages prompting usage of safer sex and drink reduction skills, which should increase self-efficacy for behavior change, and 5) access to an anonymized Community Message Board of Native women to discuss challenges in behavior change, which should increase perceived social support.

05

What researchers measure

Primary outcomes

  1. Rate of risky drinking

    Defined as binge drinking, and/or drinking over daily risk levels. Unit of measure: Rate of risky drinking Measurement tool: TLFB (timeline follow-back) of alcohol use and contraception use during sex Outcomes 1 and 2 are combined to define alcohol-exposed pregnancy risk.

    Time frame: 6 weeks

  2. Rate of ineffective/absent contraception use

    Defined per method used, or none, when having sex. Unit of measure: Rate of ineffective/absent contraception use Measurement tool: TLFB (timeline follow-back) of alcohol use and contraception use during sex Outcomes 1 and 2 are combined to define alcohol-exposed pregnancy risk.

    Time frame: 6 weeks

  3. Rate of AEP Risk

    Combination of drinking above risk levels and inconsistent or absent use of effective contraception

    Time frame: 6 weeks

06

Study locations

1 site
  • University of Virginia Fontaine Research Park
    Charlottesville, Virginia 22908, United States
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 18, 2025
  • Informed consent form · Dec 5, 2024
  • Informed consent form · Dec 5, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — We will comply with NIH data sharing protocols and will upload data to the NIAAA Data archive.

Supporting information: Study protocol, Sap, Icf

08

Registry details

Key details

Study ID
NCT06324929
Lead sponsor
University of Virginia
Collaborators
University of Minnesota, Missouri Breaks Industries Research, Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Responsible party
Lee M Ritterband (Professor Psychiatry and NB Sciences, University of Virginia) — Principal investigator
First posted
Mar 22, 2024
Start date
May 16, 2024
Primary completion
Oct 28, 2025
Completion
May 31, 2026
Last update
Jun 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion